OYST · Oyster Point Pharma Inc

-

Please sign in to comment on OYST

1 Comment

Admin

3 years, 7 months ago

Oyster Point Pharma, Inc is currently in a long term downtrend where the price is trading 14.8% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Oyster Point Pharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 12.7% to $-22M since the same quarter in the previous year.

Finally, its free cash flow fell by 28.8% to $-21M since the same quarter in the previous year.

Based on the above factors, Oyster Point Pharma, Inc gets an overall score of 1/5.

CurrencyCode	USD
Exchange	NASDAQ
Sector	Healthcare
ISIN	US69242L1061
Industry	Biotechnology

Beta	1.0
Target Price	28.6
Market Cap	186M
Dividend Yield	0.0%
PE Ratio	None

ABOUT

Oyster Point Pharma Inc

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

OYST · Oyster Point Pharma Inc

-

Oyster Point Pharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Oyster Point Pharma Inc using a moving average strategy